// App-Quantinova.ai

2525 : Phase 1/2a trial of intravenous BAL101553, a novel tumor checkpoint controller (TCC), in advanced solid tumors.

Researchers

Presenter

  • Juanita Lopez

Principal Investigators

  • Elizabeth R. Plummer

  • Nikolaos Diamantis

  • Heather May Shaw

  • Ishtiaq Husain Zubairi

  • Noor R Md Haris

  • Julie MacDonald

  • Alastair Greystoke

  • Rene Lynnette Roux

  • Nina Tunariu

  • L Rhoda Molife

  • Alison L. Hannah

  • Stephanie Anderson

  • Heidi A Lane

  • Martina Maurer

  • Anne Schmitt-Hoffmann

  • Felix Bachmann

  • Marc Frederick Engelhardt

  • Rebecca Sophie Kristeleit

Medical Centers

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom

  • Kings College London, London, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Oncology Clinical Trial Consulting, Sebastopol, CA

  • Basilea Pharmaceutica International Ltd, Basel, Switzerland

Locations

  • United States

  • United Kingdom

  • Switzerland

Companies

  • Basilea Pharmaceutic

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Circulating endothelial cells

  • Circulating tumor cells

Drug/Treatment

  • BAL-101553

Outcome

  • N/A

Study Design

  • Randomized

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT01397929

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved